ID

12971

Beschreibung

A Safety Study Comparing Natrecor (Nesiritide) Versus Dobutamine Therapy for Worsening Congestive Heart Failure; ODM derived from: https://clinicaltrials.gov/show/NCT00270400

Link

https://clinicaltrials.gov/show/NCT00270400

Stichworte

Versionen (1)
  1. 08.01.16 08.01.16 -
Rechteinhaber

CC BY-NC 3.0

Hochgeladen am

8. Januar 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Heart Failure, Congestive NCT00270400

Englisch

Eligibility Heart Failure, Congestive NCT00270400

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
history of nyha (new york heart association) class iii or iv congestive heart failure (chf)
Beschreibung

congestive heart failure

Datentyp

boolean

Alias
UMLS CUI [1]
C1275491
has symptomatic, decompensated chf for which inpatient therapy with either dobutamine or natrecor®, administered as a single intravenous vasoactive agent (drugs that influence the tone and caliber of blood vessels) with or without diuretics, is deemed appropriate
Beschreibung

has symptomatic, decompensated chf for which inpatient therapy with either dobutamine or natrecor®, administered as a single intravenous vasoactive agent (drugs that influence the tone and caliber of blood vessels) with or without diuretics, is deemed appropriate

Datentyp

boolean

Alias
UMLS CUI [1]
C0018802
UMLS CUI [2]
C0012963
UMLS CUI [3]
C0012798
receiving stable doses of oral antiarrhythmic medications (medications that help regulate irregular heart beats) for at least the 48 hours before starting study drug, or receiving no antiarrhythmic medications.
Beschreibung

oral antiarrhythmic medications

Datentyp

boolean

Alias
UMLS CUI [1]
C0003195
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
cannot tolerate a 24-hour baseline holter monitoring period without intravenous vasoactive medications, and/or cannot tolerate the specified washout period (if applicable) of intravenous vasoactive medications before starting the baseline holter monitoring
Beschreibung

cannot tolerate a 24-hour baseline holter monitoring period without intravenous vasoactive medications, and/or cannot tolerate the specified washout period (if applicable) of intravenous vasoactive medications before starting the baseline holter monitoring

Datentyp

boolean

Alias
UMLS CUI [1]
C1980011
has systolic blood pressure consistently < 85 mm hg, cardiogenic shock, or other evidence of significant hemodynamic instability requiring the immediate institution of inotropic/pressor support
Beschreibung

has systolic blood pressure consistently < 85 mm hg, cardiogenic shock, or other evidence of significant hemodynamic instability requiring the immediate institution of inotropic/pressor support

Datentyp

boolean

Alias
UMLS CUI [1]
C0005823
UMLS CUI [2]
C0036980
UMLS CUI [3]
C0948268
has a clinical condition expected to require therapy with more than one intravenous vasoactive agent or dopamine during the 24-hour treatment holter monitoring period
Beschreibung

has a clinical condition expected to require therapy with more than one intravenous vasoactive agent or dopamine during the 24-hour treatment holter monitoring period

Datentyp

boolean

Alias
UMLS CUI [1]
C1980011
UMLS CUI [2]
C0013030
has received treatment with dopamine or any intravenous vasoactive medication such as dobutamine, milrinone, nitroprusside or intravenous nitroglycerin for more than 4 hours for the current episode of decompensated chf or related illness
Beschreibung

has received treatment with dopamine or any intravenous vasoactive medication such as dobutamine, milrinone, nitroprusside or intravenous nitroglycerin for more than 4 hours for the current episode of decompensated chf or related illness

Datentyp

boolean

Alias
UMLS CUI [1]
C0013030
UMLS CUI [2]
C0012963
UMLS CUI [3]
C0128513
UMLS CUI [4]
C0028193
UMLS CUI [5]
C0017887
requires an intravenous antiarrhythmic medication during the 48 hours before starting the study
Beschreibung

requires an intravenous antiarrhythmic medication during the 48 hours before starting the study

Datentyp

boolean

Alias
UMLS CUI [1]
C0003195
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Heart Failure, Congestive NCT00270400

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
congestive heart failure
Item
history of nyha (new york heart association) class iii or iv congestive heart failure (chf)
boolean
C1275491 (UMLS CUI [1])
has symptomatic, decompensated chf for which inpatient therapy with either dobutamine or natrecor®, administered as a single intravenous vasoactive agent (drugs that influence the tone and caliber of blood vessels) with or without diuretics, is deemed appropriate
Item
has symptomatic, decompensated chf for which inpatient therapy with either dobutamine or natrecor®, administered as a single intravenous vasoactive agent (drugs that influence the tone and caliber of blood vessels) with or without diuretics, is deemed appropriate
boolean
C0018802 (UMLS CUI [1])
C0012963 (UMLS CUI [2])
C0012798 (UMLS CUI [3])
oral antiarrhythmic medications
Item
receiving stable doses of oral antiarrhythmic medications (medications that help regulate irregular heart beats) for at least the 48 hours before starting study drug, or receiving no antiarrhythmic medications.
boolean
C0003195 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
cannot tolerate a 24-hour baseline holter monitoring period without intravenous vasoactive medications, and/or cannot tolerate the specified washout period (if applicable) of intravenous vasoactive medications before starting the baseline holter monitoring
Item
cannot tolerate a 24-hour baseline holter monitoring period without intravenous vasoactive medications, and/or cannot tolerate the specified washout period (if applicable) of intravenous vasoactive medications before starting the baseline holter monitoring
boolean
C1980011 (UMLS CUI [1])
has systolic blood pressure consistently < 85 mm hg, cardiogenic shock, or other evidence of significant hemodynamic instability requiring the immediate institution of inotropic/pressor support
Item
has systolic blood pressure consistently < 85 mm hg, cardiogenic shock, or other evidence of significant hemodynamic instability requiring the immediate institution of inotropic/pressor support
boolean
C0005823 (UMLS CUI [1])
C0036980 (UMLS CUI [2])
C0948268 (UMLS CUI [3])
has a clinical condition expected to require therapy with more than one intravenous vasoactive agent or dopamine during the 24-hour treatment holter monitoring period
Item
has a clinical condition expected to require therapy with more than one intravenous vasoactive agent or dopamine during the 24-hour treatment holter monitoring period
boolean
C1980011 (UMLS CUI [1])
C0013030 (UMLS CUI [2])
has received treatment with dopamine or any intravenous vasoactive medication such as dobutamine, milrinone, nitroprusside or intravenous nitroglycerin for more than 4 hours for the current episode of decompensated chf or related illness
Item
has received treatment with dopamine or any intravenous vasoactive medication such as dobutamine, milrinone, nitroprusside or intravenous nitroglycerin for more than 4 hours for the current episode of decompensated chf or related illness
boolean
C0013030 (UMLS CUI [1])
C0012963 (UMLS CUI [2])
C0128513 (UMLS CUI [3])
C0028193 (UMLS CUI [4])
C0017887 (UMLS CUI [5])
requires an intravenous antiarrhythmic medication during the 48 hours before starting the study
Item
requires an intravenous antiarrhythmic medication during the 48 hours before starting the study
boolean
C0003195 (UMLS CUI [1])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video